MicroRNAs as candidate drug targets for cardiovascular diseases

Current Drug Targets

Volumn 17, Issue 11, 2016, Pages

  Hang, Pengzhou ^a   Guo, Jing ^a   Sun, Chuan ^a   Du, Zhimin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Arrhythmias; Biomarker; Cardiac fibrosis; Cardiac hypertrophy; Diabetes; Drug discovery; Heart failure; Hypertension; MicroRNA (miRNA); Myocardial ischemia; Therapy

Indexed keywords

ADENOSINE; APELIN; ATORVASTATIN; BERBERINE; CARVEDILOL; CHINESE DRUG; CHOLINE; DOCOSAHEXAENOIC ACID; FIBROBLAST GROWTH FACTOR; INSULIN; ISOFLURANE; IVABRADINE; LIOTHYRONINE; METFORMIN; MICRORNA; NEBIVOLOL; PIOGLITAZONE; PRASTERONE; PROPRANOLOL; ROSUVASTATIN; SILDENAFIL; TANSHINONE IIA; THIOREDOXIN 1; TONGXINLUO; TRIMETAZIDINE; UNCLASSIFIED DRUG; CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; GENE EXPRESSION; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; REVIEW; UPREGULATION; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY;

EID: 85010384350     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450117666160301101221     Document Type: Review

References (93)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2015 Update: A Report From the American Heart Association. Circulation 2015; 131: e29-322.
2. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001; 294: 862-4.
3. Friedländer MR, Lizano E, Houben AJ, et al. Evidence for the biogenesis of more than 1,000 novel human microRNAs. Genome Biol 2014; 15: R57.
4. Hata A. Functions of microRNAs in cardiovascular biology and disease. Annu Rev Physiol 2013; 75: 69-93.
5. Yang B, Lu Y, Wang Z. Control of cardiac excitability by microRNAs. Cardiovasc Res 2008; 79: 571-80.
6. Harada M, Luo X, Murohara T, Yang B, Dobrev D, Nattel S. MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. Circ Res 2014; 114: 689-705.
7. Wang Z. miRNA in the regulation of ion channel/transporter expression. Compr Physiol 2013; 3: 599-653.
8. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110: 483-95.
9. Boon RA, Dimmeler S. MicroRNAs in myocardial infarction. Nat Rev Cardiol 2015; 12: 135-42.
10. Gladka MM, da Costa Martins PA, De Windt LJ. Small changes can make a big difference-microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol 2012; 52: 74-82.
11. Thum T. Noncoding RNAs and myocardial fibrosis. Nat Rev Cardiol 2014; 11: 655-63.
12. Luo X, Yang B, Nattel S. MicroRNAs and atrial fibrillation: mechanisms and translational potential. Nat Rev Cardiol 2015; 12: 80-90.
13. Flemming A. Heart Failure: Targeting miRNA pathology in heart disease. Nat Rev Drug Discov 2014; 13: 336.
14. Bátkai S, Thum T. MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep 2012; 14: 79-87.
15. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 2012; 93: 583-93.
16. Condorelli G, Latronico MV, Cavarretta E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol 2014; 63: 2177-87.
17. Yang Y, Cheng H, Qiu Y, et al. MicroRNA-34a Plays a Key Role in Cardiac Repair and Regeneration Following Myocardial Infarction. Circ Res 2015; 117: 450-9.
18. Tolonen AM, Magga J, Szabó Z, et al. Inhibition of Let-7 microRNA attenuates myocardial remodeling and improves cardiac function postinfarction in mice. Pharmacol Res Perspect 2014; 2: e00056.
19. Hermeking, H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193-9.
20. Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009; 41: 843-8.
21. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-9.
22. Wang JX, Jiao JQ, Li Q, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med 2011; 17: 71-8.
23. Ling TY, Wang XL, Chai Q, et al. Regulation of the SK3 channel by microRNA-499--potential role in atrial fibrillation. Heart Rhythm 2013; 10: 1001-9.
24. Rottiers V, Obad S, Petri A, et al. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci Transl Med 2013; 5: 212ra162.
25. Xing Z, Li D, Yang L, Xi Y, Su X. MicroRNAs and anticancer drugs. Acta Biochim Biophys Sin (Shanghai) 2014; 46: 233-9.
26. Hang P, Han Y, Li X, Zhao J, Du Z. MicroRNAs: New players in pharmacotherapy for ischemic heart diseases? Int J Cardiol 2015; 185: 117-8.
27. Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR- 1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13: 486-91.
28. Pan Z, Sun X, Ren J, et al. miR-1 exacerbates cardiac ischemiareperfusion injury in mouse models. PLoS One 2012; 7: e50515.
29. Tang Y, Zheng J, Sun Y, Wu Z, Liu Z, Huang G. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J 2009; 50: 377-87.
30. Lu Y, Zhang Y, Shan H, et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res 2009; 84: 434-41.
31. Shan H, Li X, Pan Z, et al. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA- 1. Br J Pharmacol 2009; 158: 1227-35.
32. Zhang Y, Zhang L, Chu W, et al. Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes. Cell Physiol Biochem 2010; 26: 991-8.
33. Chen T, Ding G, Jin Z, Wagner MB, Yuan Z. Insulin ameliorates miR-1-induced injury in H9c2 cells under oxidative stress via Akt activation. Mol Cell Biochem 2012; 369: 167-74.
34. Shi YF, Liu N, Li YX, et al. Insulin protects H9c2 rat cardiomyoblast cells against hydrogen peroxide-induced injury through upregulation of microRNA-210. Free Radic Res 2015; 49: 1147-55.
35. Bostjancic E, Zidar N, Stajer D, Glavac D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 2010; 115: 163-9.
36. Zhang L, Wu Y, Li Y, et al. Tanshinone IIA improves miR-133 expression through MAPK ERK1/2 pathway in hypoxic cardiac myocytes. Cell Physiol Biochem 2012; 30: 843-52.
37. Xu C, Hu Y, Hou L, et al. β-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by upregulating miR-133 expression. J Mol Cell Cardiol 2014; 75: 111-21.
38. Suffredini S, Stillitano F, Comini L, et al. Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts fchannel overexpression. Br J Pharmacol 2012; 165: 1457-66.
39. Tabuchi T, Satoh M, Itoh T, Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci (Lond) 2012; 123: 161-71.
40. Minami Y, Satoh M, Maesawa C, et al. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur J Clin Invest 2009; 39: 359-67.
41. Forini F, Kusmic C, Nicolini G, et al. Triiodothyronine prevents cardiac ischemia/reperfusion mitochondrial impairment and cell loss by regulating miR30a/p53 axis. Endocrinology 2014; 155: 4581-90.
42. Yang Q, Yang K, Li AY. Trimetazidine protects against hypoxiareperfusion- induced cardiomyocyte apoptosis by increasing microRNA- 21 expression. Int J Clin Exp Pathol 2015; 8: 3735-41.
43. Olson JM, Yan Y, Bai X, et al. Up-regulation of microRNA-21 mediates isoflurane-induced protection of cardiomyocytes. Anesthesiology 2015; 122: 795-805.
44. Qiao S, Olson JM, Paterson M, et al. MicroRNA-21 mediates isoflurane-induced cardioprotection against ischemia-reperfusion injury via Akt/nitric oxide synthase/mitochondrial permeability Transition pore pathway. Anesthesiology. 2015; 123: 786-98.
45. Xie W, Li P, Wang Z, et al. Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR- 155/SHIP-1 signaling pathway. Cardiovasc Ther 2014; 32: 276-82.
46. Mukhopadhyay P, Mukherjee S, Ahsan K, Bagchi A, Pacher P, Das DK. Restoration of altered microRNA expression in the ischemic heart with resveratrol. PLoS One 2010; 5: e15705.
47. Mukhopadhyay P, Das S, Ahsan MK, Otani H, Das DK. Modulation of microRNA 20b with resveratrol and longevinex is linked with their potent anti-angiogenic action in the ischaemic myocardium and synergestic effects of resveratrol and γ-tocotrienol. J Cell Mol Med 2012; 16: 2504-17.
48. Rolland-Turner M, Goretti E, Bousquenaud M, et al. Adenosine stimulates the migration of human endothelial progenitor cells. Role of CXCR4 and microRNA-150. PLoS One 2013; 8: e54135.
49. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7: 589-600.
50. Zhao Y, Wang C, Wu J, et al. Choline protects against cardiac hypertrophy induced by increased after-load. Int J Biol Sci 2013; 9: 295-302.
51. Ye H, Ling S, Castillo AC, et al. Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats. Hypertension 2013; 61: 1008-13.
52. Yang Y, Ago T, Zhai P, Abdellatif M, Sadoshima J. Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. Circ Res 2011; 108: 305-13.
53. Tu Y, Wan L, Bu L, et al. MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: a new mechanism for antihypertrophic intervention. Cell Physiol Biochem 2013; 31: 997-1008.
54. Ceylan-Isik AF, Kandadi MR, Xu X, et al. Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol 2013; 63: 4-13.
55. Li X, Zhang X, Wang T, et al. Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model. J Nanosci Nanotechnol 2013; 13: 5267-75.
56. Liu F, Yin L, Zhang L, et al. Trimetazidine improves right ventricular function by increasing miR-21 expression. Int J Mol Med 2012; 30: 849-55.
57. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010; 106: 1675-80.
58. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol 2011; 8: 706-13.
59. Abonnenc M, Nabeebaccus AA, Mayr U, et al. Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA- 30c. Circ Res 2013; 113: 1138-47.
60. Zhao N, Yu H, Yu H, et al. MiRNA-711-SP1-collagen-I pathway is involved in the anti-fibrotic effect of pioglitazone in myocardial infarction. Sci China Life Sci 2013; 56: 431-9.
61. Siddesha JM, Valente AJ, Yoshida T, et al. Docosahexaenoic acid reverses angiotensin II-induced RECK suppression and cardiac fibroblast migration. Cell Signal 2014; 26: 933-41.
62. Nattel S. Decade in review--arrhythmias: Cardiac fibrillation-- challenges and evolving solutions. Nat Rev Cardiol 2014; 11: 626-7.
63. Terentyev D, Belevych AE, Terentyeva R, et al. miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res 2009; 104: 514-21.
64. Liu M, Li M, Sun S, et al. The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. Biomaterials 2014; 35: 3697-707.
65. Zhang Q, Wang G, Yuan W, Wu J, Wang M, Li C. The effects of phosphodiesterase-5 inhibitor sildenafil against post-resuscitation myocardial and intestinal microcirculatory dysfunction by attenuating apoptosis and regulating microRNAs expression: essential role of nitric oxide syntheses signaling. J Transl Med 2015; 13: 177.
66. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000; 133: 881-5.
67. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Chiaramida S. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514-6.
68. Shan H, Zhang Y, Cai B, et al. Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling. Int J Cardiol 2013; 167: 2798-805.
69. Heeringa J, Kors JA, Hofman A, van Rooij FJ, Witteman JC. Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. Am Heart J 2008; 156: 1163-9.
70. Shan H, Zhang Y, Lu Y, et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009; 83: 465-72.
71. Rafiq S, Anand S, Roberts R. Genome-wide association studies of hypertension: have they been fruitful? J Cardiovasc Transl Res 2010; 3: 189-96.
72. Nadar SK, Tayebjee MH, Messerli F, Lip GY. Target organ damage in hypertension: pathophysiology and implications for drug therapy. Curr Pharm Des. 2006; 12: 1581-92.
73. Bátkai S, Thum T. MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep 2012; 14: 79-87.
74. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15: 261-71.
75. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15: 272-84.
76. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2011; 301: H1798-809.
77. Hartmann D, Thum T. MicroRNAs and vascular (dys)function. Vascul Pharmacol 2011; 55: 92-105.
78. Caporali A, Meloni M, Völlenkle C, et al. Deregulation of microRNA- 503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011; 123: 282-91.
79. Fu X, Dong B, Tian Y, et al. MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J Clin Invest 2015; 125: 2497-509.
80. Arunachalam G, Lakshmanan AP, Samuel SM, Triggle CR, Ding H. Molecular interplay between microRNA-34a and sirtuin1 in hyperglycemia- mediated impaired angiogenesis in endothelial cells: effects of mMetformin. J Pharmacol Exp Ther 2016; 356: 314-23.
81. Hong SJ, Choi SC, Cho JY, et al. Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients-optical coherence tomography analysis. Circ J 2015; 79: 880-8.
82. Wang JY, Gao YB, Zhang N, et al. Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-tomesenchymal transition in diabetic nephropathy. Am J Physiol Renal Physiol 2014; 306: F486-95.
83. Zhao HL, Sui Y, Qiao CF, et al. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes 2012; 61: 933-43.
84. Li W, Wang J, Chen QD, et al. Insulin promotes glucose consumption via regulation of miR-99a/mTOR/PKM2 pathway. PLoS One 2013; 8: e64924.
85. Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res 2013; 72: 69-82.
86. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110: 483-95.
87. Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol 2012; 9: 850-9.
88. Pan ZW, Lu YJ, Yang BF. Advances in exploring the role of microRNAs in the pathogenesis, diagnosis and therapy of cardiac diseases in China. Br J Pharmacol 2015; 172: 5435-43.
89. Boeckel JN, Thomé CE, Leistner D, Zeiher AM, Fichtlscherer S, Dimmeler S. Heparin selectively affects the quantification of microRNAs in human blood samples. Clin Chem 2013; 59: 1125-7.
90. de Boer HC, van Solingen C, Prins J, et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J 2013; 34: 3451-7.
91. Ciccone MM, Cortese F, Gesualdo M, et al. A novel cardiac biomarker: ST2: a review. Molecules 2013; 18: 15314-28.
92. Devaux Y, Mueller M, Haaf P, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med 2015; 277: 260-71.
93. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-94.